Login

Company Executives

Management Team

From Forms 3, 4 and 5 filed in the last 18 months
Officer Age 2024 pay Source
George Lasezkay Also a director
Chief Executive Officer
73 $1,304,873

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 18, 2025 · updated by the 8-K of Aug 14, 2025

Directors
8
serving now
Independent
7 of 8
stated in the proxy
Average tenure
8.9 years
from year joined
CEO also chairs the board
No
Clay B. Thorp
Director Age On board Independent Committees Other public boards 2024 pay Source
Clay B. Thorp
56 2012
13 years
Independent None stated None stated $117,716
George Lasezkay
73 2017
8 years
Not independent None stated None stated Paid as CEO
Christy L. Shaffer
67 2012
13 years
Independent None stated None stated Not stated
Jeffrey L. Edwards
64 2018
7 years
Independent
Audit Committee
FibroGen, Inc., Bio-Rad Laboratories, Inc. $98,549
Benjamin R. Yerxa
59 2022
3 years
Independent None stated None stated Not stated
Richard Croarkin
70 2016
9 years
Independent
Audit Committee · Chair
None stated $101,049
William D. Humphries
58 2012
13 years
Independent None stated Aclaris Therapeutics, Inc. $81,049
Nancy J. Hutson
75 2020
5 years
Independent None stated BioCryst Pharmaceuticals, Inc. Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Apr 18, 2025
Bradford T. Whitmore
owns more than 5% of our common stock, together with his affiliates
$599,999.40
February 6, 2024

Purchased shares of common stock and warrants in the Company's February 2024 registered direct offering

William D. Humphries
one of our directors; served as Chief Executive Officer of Alcami from June 2023 to January 2025
Approximately $1.5 million and $0.8 million
year ended December 31, 2023 and December 31, 2024

Master Services Agreement under which Alcami provides manufacturing services to the Company; Company paid Alcami for services

With Alcami Corporation, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support